CAY10746

CAY10746 is a selective Rho kinase (ROCK) inhibitor. CAY10746 has inhibitory activity for ROCK I, ROCK II with IC50 values of 0.014 μM and 0.003 μM, respectively. CAY10746 can be used for the research of diabetic retinopathy (DR) [1].

Product Specifications

CAS Number

[2247240-76-0]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

ROCK

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton; Stem Cell/Wnt; TGF-beta/Smad

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/cay10746.html

Concentration

10mM

Purity

98.61

Solubility

DMSO : 83.33 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1C=COC2=CC(OCC(NC3=CC(NC(C4=CC=C(N(C)C)C=C4)=O)=CC=C3)=O)=CC=C12

Molecular Formula

C26H23N3O5

Molecular Weight

457.48

Precautions

H302, H315, H319

References & Citations

[1]Lanying Zhao, et al. Discovery of 4 H-Chromen-4-one Derivatives as a New Class of Selective Rho Kinase (ROCK) Inhibitors, which Showed Potent Activity in ex Vivo Diabetic Retinopathy Models. J Med Chem. 2019 Dec 12;62 (23) :10691-10710.